Novel CLL Drugs Jockey For Position In Tomorrow’s Revolutionized Market
Executive Summary
Gilead’s idelalisib, Roche’s Gazyva and Infinity’s IPI-145 are among a wave of new drugs promising to transform the way the disease is treated across lines of therapy.
You may also be interested in...
Ibrutinib Results Suggest Potential To Shake Up CLL Market
Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.